Catalyst Dossier · compiled by CeliA 🧫

Nektar Therapeutics (NKTR)

Pharmaceutical Preparations · market cap $2.1B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Nektar Therapeutics (NKTR) is a San Francisco-based biopharmaceutical company with 137 employees and a ~$2.4B market cap, built around proprietary PEGylation and polymer conjugate chemistry. Its lead asset is NKTR-181, a novel opioid in BID tablet form in Phase 3 for chronic low back pain, alongside a sprawling Phase 2 oncology and immunology pipeline. With only ~10 months of cash runway and revenues that are largely partnership/royalty-dependent, the company is navigating a binary inflection point on NKTR-181 against a tight financial clock.

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
NKTR-214	Phase 2	Unspecified Adult Solid Tumor, Protocol Specific
Bempegaldesleukin	Phase 2	Urinary Bladder Neoplasm
Rezpegaldesleukin	Phase 2	Moderate to Severe Atopic Dermatitis
LY3471851	Phase 2	Systemic Lupus Erythematosus
NKTR-102 q14d	Phase 2	Tumor
NKTR-181	Phase 2	Osteoarthritis of the Knee
NKTR-102 100 mg/m2	Phase 2	Tumor
NKTR-181 BID tablets	Phase 3	Low Back Pain
NKTR-255	Phase 2	Head and Neck Squamous Cell Carcinoma
irinotecan	Phase 2	Colorectal Cancer
Treatment of Physician's Choice (TPC)	Phase 3	Locally Recurrent Breast Cancer
NKTR-102 145 mg/m2	Phase 2	Malignant Solid Tumor
Eribulin	Phase 3	Metastasis
NKTR-102	Phase 3	Tumor

Price & technical context

3-month

-6.2%

6-month

+69.5%

12-month

+186.9%

52-wk range

$21.68–$100.35

vs 50-day MA

+0.7%

vs 200-day MA

+14.9%

Realized vol

125.6%

Max drawdown

-67.1%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for NKTR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.